INPP5D and B-cell chronic lymphocytic leukemia: Ibrutinib-treated CLL cells display higher ROS compared to untreated cells, which results in substantial inhibition of several protein phosphatases, including the B cell receptor signaling regulators SHP-1 and SHIP1 [172].